Michael Strazzella, Federal Government Relations practice group leader, comments on the recent proposal by the Department of Health and Human Services to lower the cost of prescription drugs by taking away kickback protections on rebates.

"The biggest issue in this is that everybody is pointing the finger at each other, said Mike Strazzella, practice leader, federal government relations at Buchanan Ingersoll and Rooney in D.C. "It's a larger debate. The overall goal of this rule is transparency, and less actors taking a piece of the pie in a transparent way, will drive down cost. How anyone can blame one actor around price increases is inappropriate."

Read "High Drug Prices: Who's Really to Blame?" in Healthcare Finance News.